Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balovaptan QTc interval study in healthy subjects
NCT03808298Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of balovaptan in Autism Spectrum Disorder (ASD) (12 arms), sponsored by Roche. Primary endpoint: Change-From-Baseline QTcF at Dose Level B Measured on 12-Lead ECGs Extracted From Continuous Recordings at Day 14. Started Feb 2019; status: completed.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03808298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808298.